ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 

Evaluation of the hemostatic ability of the new device Total Thrombus Formation Analysis System’ (T-TAS) for thrombocytopenic patients. In vitro effect of Thrombosomes®

1Hematopathology, Pathology Department, CDB, Hospital Clinic, IDIBAPS, University of Barcelona, Spain, Barcelona, Catalonia, Spain, 2HEMATOPATHOLOGY, PATHOLOGY DEPARTMENT, CENTRE DE DIAGNÒSTIC BIOMÈDIC. HOSPITAL CLINIC BARCELONA, BARCELONA, Catalonia, Spain, 3Hematology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Catalonia, Spain, 4Hospital Clinic Barcelona, Barcelona, Catalonia, Spain, 5Hematopathology, Department of Pathology, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, 6Josep Carreras Leukaemia Research Institute, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain., Barcelona, Catalonia, Spain, 7Cellphire Inc, Cellphire Therapeutics, Inc., Rockville, MD, US, Rockville, Maryland, United States, 8Hospital Clinic, IDIBAPS, University of Barcelona, Spain, Barcelona, Catalonia, Spain

Abstract Number: PB0854

Meeting: ISTH 2022 Congress

Theme: Platelets and Megakaryocytes » Platelet Function and Interactions

Background: Bleeding complications in thrombocytopenic patients constitute a significant problem in clinical practice. Current laboratory approaches fail to evaluate hemostasis in thrombocytopenia and also the efficacy of platelet transfusion. The Total Thrombus Formation Analysis System (T-TAS) is a new approach proposed to explore hemostasis in samples with low platelet counts. T-TAS may become an alternative tool to explore the hemostatic effect of hemoderivatives.

Aims: To validate T-TAS as a suitable device to evaluate hemostasis in samples from thrombocytopenic patients before and after platelet transfusion. To explore the hemostatic efficiency of in vitro addition of Thrombosomes®, a human platelet-derived lyophilized hemostatic agent proposed for the treatment of bleeding in thrombocytopenia.

Methods: Whole blood from hematological thrombocytopenic patients (n=28) (platelet count < 30x10^3 platelets/µl) was collected before and after platelet transfusion. Hemostasis was evaluated through T-TAS, with specific chips (HD) containing microcapillary channels (50-μm-deep) coated with collagen and tissue factor. Area under the curve (AUC) and occlusion times (OT, min) were registered for both samples before and after addition of Thrombosomes® (50x10^3/µl).

Results: Values (Mean±SEM) of platelet counts were of 10±1.2 and 24±2 (x10^3 platelets/µl) and hematocrits (HCT) were of 24±0.6% and 27±1%, before and after platelet transfusion, respectively. T-TAS demonstrated significant improvements after platelet transfusion (see Table 1). Addition of Thrombosomes® increased AUC and shortened OT in 60% and 100% of samples from non-transfused (p˂0.05) and transfused patients, respectively.

Conclusion(s): The newly designed system T-TAS, using a modified microchip-based flow chamber, was able to measure hemostasis in samples with thrombocytopenia and low hematocrit. T-TAS was useful to evaluate the hemostatic capacity of transfused platelets. Moreover, T-TAS offers a platform to assess the hemostatic effect of hemoderivatives, such as Thrombosomes®, which enabled hemostasis even in those samples in which it was severely impaired.

Table

Table 1. T-TAS parameters -AUC and OT; Mean±SEM- obtained in samples from thrombocytopenic patients before and after platelet transfusion. In vitro effect of Thrombosomes®.

To cite this abstract in AMA style:

Samanbar S, Moreno-Castaño A, Piñeyroa J, Pino M, Torramade-Moix S, Martinez-Sanchez J, Moskowitz K, Escolar G, Diaz-Ricart M. Evaluation of the hemostatic ability of the new device Total Thrombus Formation Analysis System’ (T-TAS) for thrombocytopenic patients. In vitro effect of Thrombosomes® [abstract]. https://abstracts.isth.org/abstract/evaluation-of-the-hemostatic-ability-of-the-new-device-total-thrombus-formation-analysis-system-t-tas-for-thrombocytopenic-patients-in-vitro-effect-of-thrombosomes/. Accessed October 1, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-the-hemostatic-ability-of-the-new-device-total-thrombus-formation-analysis-system-t-tas-for-thrombocytopenic-patients-in-vitro-effect-of-thrombosomes/